Coronavirus Scientific Advisory Board

Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 21, 2023
Molecular biology, GMP, SAB, Exercise, Good, Business development, Partnership, Drug development, Biochemistry, Marketing, Biotechnology, Cancer, Quality of life, Coronavirus Scientific Advisory Board, Intelligence, Wall Street, MBA, Research, Genomics, Cell, CLIA, Acquisition, Patient, Good manufacturing practice, CBO, Machine learning, ACE, Corporation, Drug discovery, Artificial intelligence, Growth, Piper, Foundation Medicine, DLA Piper, Pharmaceutical industry, Cryptocurrency, Medical imaging, Management, Security (finance), IP

Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.

Key Points: 
  • Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.
  • Appointed Pamela Bush, Ph.D., MBA, as Chief Business Officer (CBO) to lead the company’s business development, partnering and growth initiatives.
  • The consolidated reportable segments of Predictive Oncology recorded revenue of $1,505,459 in 2022, compared to $1,420,680 in 2021.
  • We incurred net losses of $25,737,634 and $19,657,174 for the years ended December 31, 2022, and December 31, 2021, respectively.

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

Retrieved on: 
Tuesday, March 21, 2023
Research, Professional Services, Pharmaceutical, Data Management, Technology, Health Technology, Data Analytics, Science, Biotechnology, Consulting, Other Science, Health, Drug development, Astellas Pharma, IQVIA, Coronavirus Scientific Advisory Board, MMS, Infection, Pain, Lilly, Patient, Pivotal, Growth, Nursing care plan, Pfizer, Pharmaceutical industry, Nursing, Development

MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.

Key Points: 
  • MMS Holdings, an award-winning, data-focused CRO, announced today the addition of Dr. Philip Breitfeld and Dr. Bernhardt Zeiher to its board of scientific advisors.
  • Both industry leaders in innovative clinical trial delivery solutions, Dr. Breitfeld and Dr. Zeiher’s additions as advisors expand MMS’ therapeutic area expertise to support growth in different therapeutic areas.
  • “We are pleased to welcome Dr. Breitfeld and Dr. Zeiher to our Scientific Advisory Board,” said Uma Sharma, Ph.D., CEO of MMS.
  • “At MMS, we work with our sponsors to support the development of groundbreaking therapies and bring them to market.

PaxMedica Holds Meeting of Scientific Advisory Board

Retrieved on: 
Monday, March 20, 2023
University of California, San Diego Performance-Based Skills Assessment, Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, Suramin, University, Pediatrics, State University of New York Upstate Medical University, Autism spectrum, Spectrum, Baylor University, Coronavirus Scientific Advisory Board, Doctor of Philosophy, Disorder, MD, Pathology, ASD, Behavioural sciences, Baylor College of Medicine, VCU School of Medicine, Pharmaceutical industry, Psychiatry, Medicine

TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.  A number of new members have been added to the board, which consists of many key opinion leaders in autism spectrum disorder (ASD) in the United States including:

Key Points: 
  • Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.
    TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it held a Scientific Advisory Board meeting on March 10-12, 2023.
  • We continue to be very excited about studying a product for the potential treatment of the core symptoms of autism spectrum disorder.”
    Dr. Robert Naviaux added, “At the scientific advisory board meeting this weekend, experts from many different areas of medicine came together to share their thoughts on how suramin may work in ASD and how it might work in several other complex disorders.
  • What emerged was a clear vision for the next steps needed to test suramin in autism.
  • This is expected to be done in a series of international, multicenter, clinical trials that are projected to begin in 2024.”

Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases

Retrieved on: 
Monday, March 20, 2023
Research, Other Health, Pharmaceutical, Oncology, Consumer, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Seniors, Health, Other Science, Senior, Drug discovery, Department of Medicine – University of Pamplona, Histopathology, Ageing, Coronavirus Scientific Advisory Board, American Academy, Multimedia, Dermatitis, Cell, Inflammation, Psoriasis, Hair, Dermatology, Professor, Physician, AAD, Memorial Sloan Kettering Cancer Center, Rubedo, Pharmaceutical industry, Management, Vaccine

Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.

Key Points: 
  • Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.
  • The focus of the annual conference is to help dermatological professionals learn about the latest industry updates and research.
  • View the full release here: https://www.businesswire.com/news/home/20230320005208/en/
    Ofir Moreno, Ph.D., is Senior Vice President, Drug Discovery at Rubedo, presenting at the OncoDermatology Society conference.
  • Leveraging its proprietary single-cell multiomics platform ALEMBIC™, Rubedo identifies pathologic cells with senescence features characteristic of multiple dermatological chronic skin conditions, and is developing potent and selective compounds targeting those cells using its selective senolytic platform SenTech™.

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

Retrieved on: 
Monday, March 20, 2023
DNA, Index, MOA, Therapy, Neoplasm, Poly (ADP-ribose) polymerase, Nutrient, Coronavirus Scientific Advisory Board, Gynecologic Oncology (journal), Moa, Associate, MS, Blood, Downregulation and upregulation, Patient, Mass, Clinical research, HR, MTD, Growth, Fibroblast growth factor receptor, Principal, Ovarian cancer, Death, PARP, PTK, Homologous recombination, Safety, Pharmaceutical industry, Medical imaging, MD

“Having investigated novel combinations of anticancer agents, including a PARP inhibitor and an anti-angiogenic therapeutic, we have seen improved efficacy.

Key Points: 
  • “Having investigated novel combinations of anticancer agents, including a PARP inhibitor and an anti-angiogenic therapeutic, we have seen improved efficacy.
  • The Phase 1b trial is designed with a target enrollment of up to 36 patients with advanced solid tumors, focusing on specific tumor types that Allarity anticipates will be most responsive to the drug combination.
  • Researchers will analyze patient tumor samples retrospectively using Allarity’s DRP® companion diagnostics for stenoparib and dovitinib.
  • Allarity holds exclusive, global commercial rights to both dovitinib and stenoparib.

Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22

Retrieved on: 
Friday, March 17, 2023
SAB, Great Industrial Exhibition (1853), Learning, SARS-CoV-2, Institute of technology, NGS, Chain reaction, Food and Drug Administration, Infection, Liquid biopsy, Trade fair, Coronavirus Scientific Advisory Board, Biomarker, SALT, CNA, Sale, Real-time, Exhibition, Diagnosis, FDA, PCR, Food, Technical University of Munich, Pharmaceutical industry

SALT LAKE CITY, March 17, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 10th Gene Quantification Event held March 20-24 at the Technical University of Munich. Dr. Carl Wittwer, Chair of the Company's Scientific Advisory Board (SAB) will also be presenting at the event.

Key Points: 
  • Dr. Carl Wittwer, Chair of the Company's Scientific Advisory Board (SAB) will also be presenting at the event.
  • To learn more about the event, including in-person and virtual registration details, please visit https://www.gene-quantification.de/GQ2023/ .
  • Attendees interested in learning more about the Company and its products, including its upcoming Co-Dx PCR Home platform, are invited to visit Booth 7 in the Industrial Exhibition.
  • *The Co-Dx PCR Home platform is subject to U.S. Food and Drug Administration ("FDA") review and has not been cleared or approved for sale.

Co-Diagnostics, Inc. Reports Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 16, 2023
SALT, POC, Research, Sale, Webcast, Tobacco Products Scientific Advisory Committee, EDT, HPV, Consolidated Revenue Fund of Canada, Investment, M.D, COVID-19, FDA, Coronavirus Scientific Advisory Board, JV, Infection, PCR, Medical device, Cryptocurrency, Vaccine, Pharmaceutical industry

SALT LAKE CITY, March 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022.

Key Points: 
  • SALT LAKE CITY, March 16, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022.
  • The commencement of clinical evaluations announced in February of this year marks an important step toward detection of infectious diseases in at-home and POC settings, with anticipated multiplex panels to follow."
  • Mr. Egan continued, "Looking ahead, we remain focused on executing the clinical evaluations for our Co-Dx PCR Home platform, including the clinical trials themselves and the analytical studies required to support regulatory submissions.
  • Our mission of creating a new standard for real-time PCR at-home and POC technology continues to be validated.

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 16, 2023
Cancer, Research, Conference, Autoimmunity, University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cyclophosphamide, Partnership, CAR, SLE, Maintenance, University of Pennsylvania, Lancet, Patient, Autoimmune disease, MG, Autoantibody, Investment, CD19, FDA, Disease, Nature Biotechnology, Immunoglobulin therapy, Clinical trial, Immune system, Investigational New Drug, MuSK protein, Coronavirus Scientific Advisory Board, Food, Drug discovery, IND, Syndrome, Recurrence, Pharmaceutical industry, Cryptocurrency, Cabaletta

PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • We believe the tolerability data reported by IASO in these patients support clinical development in patients with autoimmune diseases.
  • These data were developed through a sponsored research agreement between Cabaletta Bio and University of Pennsylvania professor Aimee Payne, M.D., Ph.D., Cabaletta Bio co-founder and Scientific Advisory Board co-chair.
  • As of December 31, 2022, Cabaletta had cash, cash equivalents and investments of $106.5 million, compared to $122.2 million as of December 31, 2021.
  • The Company expects that its cash, cash equivalents and investments as of December 31, 2022, will enable it to fund its operating plan into the first quarter of 2025.

FDA Gives Greenlight for Bobbie’s First of its Kind Tolerance Formula, Expanding Product Offering and Supporting More American Babies with High-Quality, Domestically Manufactured Organic Infant Formula

Retrieved on: 
Thursday, March 16, 2023
Parenting, FDA, Baby, Maternity, Fitness & Nutrition, Food, Beverage, Health, Consumer, Retail, Organic Food, Multimedia, Research, ARA, Medical research, Infant, Parent, Risk, Science and technology in Asia, Weight gain, Yale University, Life, Doctor of Pharmacy, Obesity, Protein, Science, DHA, Toddler, Perrigo, Lactose, Whey, AAP, Mother, Associate, Growth, Milk, Infant formula, Breast milk, Coronavirus Scientific Advisory Board, Organic, Cosmetics, Dairy, Dietary supplement, Toy, MD, RD, EU, Pediatrics, MPH, FAAP

Meet our new baby, Bobbie® Organic Gentle® -- due late Spring 2023. (Photo: Business Wire)

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230316005244/en/
    Meet our new baby, Bobbie® Organic Gentle® -- due late Spring 2023.
  • (Photo: Business Wire)
    Bobbie has never sacrificed their commitment to high-quality, organic ingredients—and are proud to expand this promise to parents seeking a tolerance formula with partially hydrolyzed protein.
  • Bobbie’s VP of Regulatory, Christina Berberich, PharmD, MPH, RD, and Mother worked with Perrigo to bring this ideal product into existence with Bobbie’s Organic Gentle Infant Formula.
  • “We established Bobbie Labs to evolve infant feeding while shaking the formula stigma within the research community and beyond.

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology

Retrieved on: 
Tuesday, March 14, 2023
ACT, AstraZeneca, Cancer, Acquisition, United Kingdom, Workforce, Medicine, Chairperson, Genomics, Chinese University of Hong Kong, Chinese, Patient, Nature, Investment, EBITDA, COVID-19, FDA, Communication, Growth, Coronavirus Scientific Advisory Board, Social responsibility, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, Renewable energy, Video game, Insurance, Bank, Artisan

-- Cash and other short-term assets of US$242.1 million as of December 31, 2022

Key Points: 
  • -- Cash and other short-term assets of US$242.1 million as of December 31, 2022
    -- Embarked on a new business strategy focused on precision oncology, as the Company exits the COVID-19 testing business.
  • Furthermore, I am immensely optimistic with our new business strategy in precision oncology.
  • Prenetics is focusing its business strategy to genomics and precision oncology, and is dedicated to transforming patients' care through advanced genomic and molecular technologies.
  • -- Adjusted EBITDA was US$12.1 million for the fourth quarter 2022 compared to US$(5.9) million for the fourth quarter 2021.